Funding Opportunities & Resources
As COVID-19 spreads across the globe, new research funding opportunities are cropping up – along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. This page is meant to answer those questions and provide information on new opportunities to all researchers at UR.
Funding Opportunities and Guidance
Any federal funding guidance associated with potential COVID-19-related disruptions to research will be shared by the Office of Research and Project Administration (ORPA). Contact your designated research administrator for additional information or to coordinate notification of regulatory and funding agencies.
The Council on Government Relations (COGR) is regularly updating information on responses to COVID-19 from its institutions and agencies (including NIH, NSF, DoD, CDC, EPA, etc). Learn more and review FAQs and memos from COGR.
You can also search Grants.gov for coronavirus-related opportunities from government agencies including CDC, HHS, USDA, US Army and more.
Department of Health and Human Services
White House Office of Management and Budget
National Science Foundation
NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals with a severe urgency regarding quick-response research on natural or anthropogenic disasters and similar unanticipated events. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to firstname.lastname@example.org.
Edge For Scholars
Edge for Scholars, a community for candid conversation about life in academics, has curated an extensive list of COVID-19-related funding opportunities. Check their page for anything we might have missed here.
Wellcome and Bill & Melinda Gates Foundations
- The Wellcome Trust has released an Epidemic Preparedness: COVID-19 Funding Call for studies investigating new approaches for preventing and controlling COVID-19 with a focus on helping low- and middle-income countries prepare for and deal with the epidemic. There are no deadlines. Expressions of interest should be submitted as soon as possible.
- The Wellcome and Gates Foundation teams are currently assessing research priorities and labs that have required expertise and capacity for their COVID-19 Therapeutics Accelerator. If you have a specific proposal, please send to:
- The UR CTSI offers a software tool for patient cohort discovery, called TriNetx, that queries data from the URMC EHR and returns the number of patients that fit specific research queries. Please review the instructions on how to use TriNetx to query for specific diagnoses and labs related to COVID-19 testing and illness and reach out to UR CTSI Informatics at CTSI_Informatics@URMC.Rochester.edu if you have any questions.
- The UR CTSI has collated boilerplate language for URMC research facilities and resources to use in grant applications.
- The NIH Office of Data Science Strategy is regularly updating a list of open-access data and computational resources to address COVID-19 that are freely available to researchers.
- The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its BEI Resources Repository.
- Request access to resources of the COVID-19 High Performance Computing Consortium,a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines.
Access the Allen Institute for AI's COVID-19 Open Research Dataset (CORD-19), a free resource of over 52,000 scholarly articles, including over 41,000 with full text, about COVID-19 and the coronavirus family of viruses for use by the global research community.
Gingko Bioworks, an American biotech and analytics company, has committed $25M of free access to their bio-manufacturing platform for partner COVID-19 projects. If you are developing a diagnostic, drug, or vaccine and are interested in leveraging Ginkgo’s infrastructure at no cost please email email@example.com.